An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase 2CompletedNCT01909427

Janssen Research & Development, LLC257 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of CNTO6785 in participants with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.

This is a randomized (participants are assigned to treatment by chance), double-blind (participants and study personnel will not know which treatments are being given), placebo-controlled (a placebo appears identical to a study drug but has no active ingredients), multicenter study. The study will consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase. Approximately 250 participants with active RA despite MTX therapy will be randomly assigned to receive placebo or CNTO 6785 during the double-blind treatment phase. The maximum period of active treatment will be 28 weeks. The maximum duration of study participation will be 44 weeks. Participant safety will be monitored throughout the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

257

Conditions

Rheumatoid Arthritis

Interventions

PlaceboDRUG

Placebo subcutaneous injections (SC) every 4 weeks through Week 12

CNTO 6785 200 mgDRUG

CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28

CNTO 6785 200 mgDRUG

CNTO 6785 200 mg SC every 4 weeks through Week 28

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the American Rheumatism Association) and have had RA for at least 6 months prior to the date of signing the informed consent at screening * Have active RA defined study as persistent disease activity with both of the following criteria: at least 6 swollen and 6 tender joints using a 66/68 joint count at the time of screening and at baseline; and serum C-reactive protein (CRP) ≥ 0.8 mg/dL at screening or erythrocyte sedimentation rate (ESR) ≥ 28 mm in the first hour at screening or baseline * Have been treated with and tolerated methotrexate (MTX) treatment at dosages from 7.5 to 25 mg/week, inclusive, for a minimum of 6 months prior to screening and must have a stable MTX dose for a minimum of 6 weeks prior to the first dosing with study agent Exclusion Criteria: * Has inflammatory diseases other than RA, that might confound the evaluation of the benefit of study agent therapy * Has a diagnosis of fibromyalgia * Has a recent history (within 12 months prior to screening) of uncontrolled, chronic disease including, but not limited to, pulmonary, psychiatric, and metabolic disturbances, cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, or urological diseases that the investigator believes are clinically significant * At screening, the results of laboratory tests must meet protocol-specified criteria * Has ever received any approved or investigational biologic agent for a rheumatic indication

Locations (32)

Unnamed facility

Buenos Aires, Argentina

Unnamed facility

Ciudad Autonoma Buenos Aires, Argentina

Outcomes

Primary Outcomes

The proportion of participants who achieve an ACR 20 response at Week 16

American College of Rheumatology (ACR) 20 response is a \>=20% improvement in rheumatoid arthritis (RA) symptoms.

Time frame: Week 16

Secondary Outcomes

Change from baseline in DAS28 (CRP) at Week 16

DAS28 (using CRP \[C-reactive protein\]) is a measure of tender and swollen joints and the patient's assessment of disease activity.

Time frame: Baseline to Week 16

The proportion of participants who achieve ACR 50 response at Week 16

American College of Rheumatology (ACR) 50 response is a \>=50% improvement in rheumatoid arthritis (RA) symptoms.

Time frame: Week 16

The proportion of participants who achieve ACR 20 response through Week 32

Time frame: Week 32

The proportion of participants who achieve ACR 50 response through Week 32

Time frame: Week 32

The proportion of participants who achieve ACR 70 response through Week 32

American College of Rheumatology (ACR) 70 response is a \>=70% improvement in rheumatoid arthritis (RA) symptoms.

Time frame: Week 32

Change from baseline of DAS28 (CRP) through Week 32

Time frame: Baseline to Week 32

The proportion of participants with DAS28 (CRP) response through Week 32

DAS28 (using CRP \[C-reactive protein\]) response is improvement from baseline, with \>1.2 indicating a good or moderate response and \<=0.6 indicating no response.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

CNTO 6785 100 mg SC every 4 weeks through Week 28

CNTO 6785 50 mgDRUG

CNTO 6785 50 mg SC every 4 weeks through Week 28

CNTO 6785 15 mgDRUG

CNTO 6785 15 mg SC every 4 weeks through Week 28

Methotrexate (MTX)DRUG

MTX at the same stable dose through Week 32, that participants were receiving prior to screening.

Unnamed facility

Córdoba, Argentina

Unnamed facility

La Capital, Argentina

Unnamed facility

San Juan, Argentina

Unnamed facility

Barranquilla, Colombia

Unnamed facility

Bogotá, Colombia

Unnamed facility

Medellín, Colombia

Unnamed facility

Jihlava, Czechia

Unnamed facility

Prague, Czechia

...and 22 more locations

The proportion of participants with DAS28 (CRP) remission at Week 16

DAS28 (using CRP \[C-reactive protein\]) remission is defined as a value of \<2.6 on the Disease Activity Index, a measure of tender and swollen joints and the patient's assessment of disease activity.

Time frame: Week 16

The proportion of participants with DAS28 (CRP) remission at Week 32

Time frame: Week 32

Change from baseline in DAS28 (ESR) at Week 16

DAS28 (using erythrocyte sedimentation rate) is a measure of tender and swollen joints and the patient's assessment of disease activity.

Time frame: Baseline to Week 16

Change from baseline in DAS28 (ESR) at Week 32

Time frame: Baseline to Week 32

Change from baseline in HAQ-DI score through Week 32

The Health Assessment Questionnaire-Disability Index (HAQ-DI) assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas, each scored from 0 (no difficulty) to 3 (inability to perform a task).

Time frame: Baseline to Week 32

Change from baseline in SF-36 at Week 16

The SF-36 is a medical outcome study health measure and consists of 8 multi-item scales that are scored from 0 to 100, with higher scores indicating better health.

Time frame: Baseline to Week 16

Change from baseline in SF-36 at Week 32

Time frame: Baseline to Week 32

Change from baseline in CDAI at Week 16

Clinical Disease Activity Index (CDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, and Physician's Global Assessments of Disease Activity.

Time frame: Baseline to Week 16

Change from baseline in CDAI at Week 32

Time frame: Baseline to Week 32

Change from baseline in SDAI at Week 16

The Simplified Disease Activity Index (SDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, Physician's Global Assessments of Disease Activity, and CRP.

Time frame: Baseline to Week 16

Change from baseline in SDAI at Week 32

Time frame: Baseline to Week 32

The proportion of participants with SDAI-based ACR/EULAR remission at Week 16

The Simplified Disease Activity Index (SDAI)-based ACR/EULAR (European League Against Rheumatism) remission is defined as a SDAI value of \<=3.3 at a visit.

Time frame: Week 16

The proportion of participants with SDAI-based ACR/EULAR remission at Week 32

Time frame: Week 32

The proportion of participants with Boolean-based ACR/EULAR remission at Week 16

Boolean-based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) \<=1; swollen joint count (66 joints) \<=1; CRP \<=1 mg/dL; and Patient's Global Assessment of Disease Activity on VAS \<=1 on a 0 to 10 scale.

Time frame: Week 16

The proportion of participants with Boolean-based ACR/EULAR remission at Week 32

Time frame: Week 32